schliessen

Filtern

 

Bibliotheken

Cover Image

Comparison Between Valsartan and Amlodipine Regarding Cardiovascular Morbidity and Mortality in Hypertensive Patients With Glucose Intolerance: NAGOYA HEART Study

It has not been fully examined whether angiotensin II receptor blocker is superior to calcium channel blocker to reduce cardiovascular events in hypertensive patients with glucose intolerance. A prospective, open-labeled, randomized, controlled trial was conducted for Japanese hypertensive patients... Full description

Journal Title: Hypertension (Dallas Tex. 1979), 2012-03, Vol.59 (3), p.580-586
Main Author: Muramatsu, Takashi
Other Authors: Matsushita, Kunihiro , Yamashita, Kentaro , Kondo, Takahisa , Maeda, Kengo , Shintani, Satoshi , Ichimiya, Satoshi , Ohno, Miyoshi , Sone, Takahito , Ikeda, Nobuo , Watarai, Masato , Murohara, Toyoaki
Format: Electronic Article Electronic Article
Language: English
Subjects:
Amlodipine - therapeutic use
Antihypertensive agents
Antihypertensive Agents - therapeutic use
Arterial hypertension. Arterial hypotension
Biological and medical sciences
Blood and lymphatic vessels
Blood Glucose - metabolism
Blood Pressure - drug effects
Cardiology. Vascular system
Cardiovascular system
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - epidemiology
Female
Follow-Up Studies
Glucose Intolerance
Glycated Hemoglobin A - metabolism
Humans
Hypertension - complications
Hypertension - drug therapy
Hypertension - epidemiology
Japan - epidemiology
Male
Medical sciences
Middle Aged
Morbidity - trends
Pharmacology. Drug treatments
Prospective Studies
Risk Factors
Survival Rate - trends
Tetrazoles - therapeutic use
Valine - analogs & derivatives
Valine - therapeutic use
Valsartan
Publisher: Hagerstown, MD: American Heart Association, Inc
ID: ISSN: 0194-911X
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_948902778
title: Comparison Between Valsartan and Amlodipine Regarding Cardiovascular Morbidity and Mortality in Hypertensive Patients With Glucose Intolerance: NAGOYA HEART Study
format: Article
creator:
  • Muramatsu, Takashi
  • Matsushita, Kunihiro
  • Yamashita, Kentaro
  • Kondo, Takahisa
  • Maeda, Kengo
  • Shintani, Satoshi
  • Ichimiya, Satoshi
  • Ohno, Miyoshi
  • Sone, Takahito
  • Ikeda, Nobuo
  • Watarai, Masato
  • Murohara, Toyoaki
subjects:
  • Amlodipine - therapeutic use
  • Antihypertensive agents
  • Antihypertensive Agents - therapeutic use
  • Arterial hypertension. Arterial hypotension
  • Biological and medical sciences
  • Blood and lymphatic vessels
  • Blood Glucose - metabolism
  • Blood Pressure - drug effects
  • Cardiology. Vascular system
  • Cardiovascular system
  • Diabetes Mellitus, Type 2 - blood
  • Diabetes Mellitus, Type 2 - complications
  • Diabetes Mellitus, Type 2 - epidemiology
  • Female
  • Follow-Up Studies
  • Glucose Intolerance
  • Glycated Hemoglobin A - metabolism
  • Humans
  • Hypertension - complications
  • Hypertension - drug therapy
  • Hypertension - epidemiology
  • Japan - epidemiology
  • Male
  • Medical sciences
  • Middle Aged
  • Morbidity - trends
  • Pharmacology. Drug treatments
  • Prospective Studies
  • Risk Factors
  • Survival Rate - trends
  • Tetrazoles - therapeutic use
  • Valine - analogs & derivatives
  • Valine - therapeutic use
  • Valsartan
ispartof: Hypertension (Dallas, Tex. 1979), 2012-03, Vol.59 (3), p.580-586
description: It has not been fully examined whether angiotensin II receptor blocker is superior to calcium channel blocker to reduce cardiovascular events in hypertensive patients with glucose intolerance. A prospective, open-labeled, randomized, controlled trial was conducted for Japanese hypertensive patients with type 2 diabetes mellitus or impaired glucose tolerance. A total of 1150 patients (women34%; mean age63 years; diabetes mellitus82%) were randomly assigned to receive either valsartan- or amlodipine-based antihypertensive treatment. Primary outcome was a composite of acute myocardial infarction, stroke, coronary revascularization, admission attributed to heart failure, or sudden cardiac death. Blood pressure was 145/82 and 144/81 mm Hg, and glycosylated hemoglobin was 7.0% and 6.9% at baseline in the valsartan group and the amlodipine group, respectively. Both of them were equally controlled between the 2 groups during the study. The median follow-up period was 3.2 years, and primary outcome had occurred in 54 patients in the valsartan group and 56 in the amlodipine group (hazard ratio0.97 [95% CI0.66–1.40]; P=0.85). Patients in the valsartan group had a significantly lower incidence of heart failure than in the amlodipine group (hazard ratio0.20 [95% CI0.06–0.69]; P=0.01). Other components and all-cause mortality were not significantly different between the 2 groups. Composite cardiovascular outcomes were comparable between the valsartan- and amlodipine-based treatments in Japanese hypertensive patients with glucose intolerance. Admission because of heart failure was significantly less in the valsartan group.
language: eng
source:
identifier: ISSN: 0194-911X
fulltext: no_fulltext
issn:
  • 0194-911X
  • 1524-4563
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.483761
LOCALfalse
PrimoNMBib
record
control
sourceidproquest_cross
recordidTN_cdi_proquest_miscellaneous_948902778
sourceformatXML
sourcesystemPC
sourcerecordid948902778
originalsourceidFETCH-LOGICAL-14406-684326a431bb96e7f4e0dd4f99838648905284a5e4574ba1059b7cd9bcdcd590
addsrcrecordideNqNUV1v0zAUjRCIlcFfQBYS4inDdpyvPZFVpa002qmrgD1FTny7Ghy72M6q_h1-KQ4tIO0JS9bVuTr3-PieKHpD8AUhGXk_u7uZrNaTxe18uahmVWiSC1IwSrMn0YiklMUszZKn0QiTksUlIV_PohfOfcOYMMby59EZpTShJGGj6OfYdDtupTMaXYHfA2j0mSvHrecacS1Q1Skj5E5qQCu451ZIfY_GQzUP3LW94hZ9MraRQvrD74mAPFcDkhrNDjuwHrSTD4BuuJegvUNfpN-iqepb4wDNtTcKLNctXKJFNV3eVWg2qVZrdOt7cXgZPdsER_DqVM-j9cfJejyLr5fT-bi6jsOvcBZnBUtoxllCmqbMIN8wwEKwTVkWSZGxosQpLRhPgaU5azjBadnkrSibVrQiLfF59O4ou7PmRw_O1510LSjFNZje1eUgQfO8CMzLI7O1xjkLm3pnZcftoSa4HhKqHyUUmqQ-JhSGX5-e6ZsOxN_RP5EEwtsTIWyXq82wF-n-8dKUJpgNLj48ctFKH_ZrtLdcqv_zwo4Se6M8WPdd9Xuw9Ra48tsah8NoVsQUE4qTgOJwSYZ_AWDJwWw
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid948902778
display
typearticle
titleComparison Between Valsartan and Amlodipine Regarding Cardiovascular Morbidity and Mortality in Hypertensive Patients With Glucose Intolerance: NAGOYA HEART Study
creatorMuramatsu, Takashi ; Matsushita, Kunihiro ; Yamashita, Kentaro ; Kondo, Takahisa ; Maeda, Kengo ; Shintani, Satoshi ; Ichimiya, Satoshi ; Ohno, Miyoshi ; Sone, Takahito ; Ikeda, Nobuo ; Watarai, Masato ; Murohara, Toyoaki
creatorcontribMuramatsu, Takashi ; Matsushita, Kunihiro ; Yamashita, Kentaro ; Kondo, Takahisa ; Maeda, Kengo ; Shintani, Satoshi ; Ichimiya, Satoshi ; Ohno, Miyoshi ; Sone, Takahito ; Ikeda, Nobuo ; Watarai, Masato ; Murohara, Toyoaki ; NAGOYA HEART Study Investigators ; for the NAGOYA HEART Study Investigators
descriptionIt has not been fully examined whether angiotensin II receptor blocker is superior to calcium channel blocker to reduce cardiovascular events in hypertensive patients with glucose intolerance. A prospective, open-labeled, randomized, controlled trial was conducted for Japanese hypertensive patients with type 2 diabetes mellitus or impaired glucose tolerance. A total of 1150 patients (women34%; mean age63 years; diabetes mellitus82%) were randomly assigned to receive either valsartan- or amlodipine-based antihypertensive treatment. Primary outcome was a composite of acute myocardial infarction, stroke, coronary revascularization, admission attributed to heart failure, or sudden cardiac death. Blood pressure was 145/82 and 144/81 mm Hg, and glycosylated hemoglobin was 7.0% and 6.9% at baseline in the valsartan group and the amlodipine group, respectively. Both of them were equally controlled between the 2 groups during the study. The median follow-up period was 3.2 years, and primary outcome had occurred in 54 patients in the valsartan group and 56 in the amlodipine group (hazard ratio0.97 [95% CI0.66–1.40]; P=0.85). Patients in the valsartan group had a significantly lower incidence of heart failure than in the amlodipine group (hazard ratio0.20 [95% CI0.06–0.69]; P=0.01). Other components and all-cause mortality were not significantly different between the 2 groups. Composite cardiovascular outcomes were comparable between the valsartan- and amlodipine-based treatments in Japanese hypertensive patients with glucose intolerance. Admission because of heart failure was significantly less in the valsartan group.
identifier
0ISSN: 0194-911X
1EISSN: 1524-4563
2DOI: 10.1161/HYPERTENSIONAHA.111.184226
3PMID: 22232134
4CODEN: HPRTDN
languageeng
publisherHagerstown, MD: American Heart Association, Inc
subjectAmlodipine - therapeutic use ; Antihypertensive agents ; Antihypertensive Agents - therapeutic use ; Arterial hypertension. Arterial hypotension ; Biological and medical sciences ; Blood and lymphatic vessels ; Blood Glucose - metabolism ; Blood Pressure - drug effects ; Cardiology. Vascular system ; Cardiovascular system ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - epidemiology ; Female ; Follow-Up Studies ; Glucose Intolerance ; Glycated Hemoglobin A - metabolism ; Humans ; Hypertension - complications ; Hypertension - drug therapy ; Hypertension - epidemiology ; Japan - epidemiology ; Male ; Medical sciences ; Middle Aged ; Morbidity - trends ; Pharmacology. Drug treatments ; Prospective Studies ; Risk Factors ; Survival Rate - trends ; Tetrazoles - therapeutic use ; Valine - analogs & derivatives ; Valine - therapeutic use ; Valsartan
ispartofHypertension (Dallas, Tex. 1979), 2012-03, Vol.59 (3), p.580-586
rights
02012 American Heart Association, Inc.
12015 INIST-CNRS
lds50peer_reviewed
oafree_for_read
citedbyFETCH-LOGICAL-14406-684326a431bb96e7f4e0dd4f99838648905284a5e4574ba1059b7cd9bcdcd590
citesFETCH-LOGICAL-14406-684326a431bb96e7f4e0dd4f99838648905284a5e4574ba1059b7cd9bcdcd590
links
openurl$$Topenurl_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25523048$$DView record in Pascal Francis
1$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22232134$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Muramatsu, Takashi
1Matsushita, Kunihiro
2Yamashita, Kentaro
3Kondo, Takahisa
4Maeda, Kengo
5Shintani, Satoshi
6Ichimiya, Satoshi
7Ohno, Miyoshi
8Sone, Takahito
9Ikeda, Nobuo
10Watarai, Masato
11Murohara, Toyoaki
12NAGOYA HEART Study Investigators
13for the NAGOYA HEART Study Investigators
title
0Comparison Between Valsartan and Amlodipine Regarding Cardiovascular Morbidity and Mortality in Hypertensive Patients With Glucose Intolerance: NAGOYA HEART Study
1Hypertension (Dallas, Tex. 1979)
addtitleHypertension
descriptionIt has not been fully examined whether angiotensin II receptor blocker is superior to calcium channel blocker to reduce cardiovascular events in hypertensive patients with glucose intolerance. A prospective, open-labeled, randomized, controlled trial was conducted for Japanese hypertensive patients with type 2 diabetes mellitus or impaired glucose tolerance. A total of 1150 patients (women34%; mean age63 years; diabetes mellitus82%) were randomly assigned to receive either valsartan- or amlodipine-based antihypertensive treatment. Primary outcome was a composite of acute myocardial infarction, stroke, coronary revascularization, admission attributed to heart failure, or sudden cardiac death. Blood pressure was 145/82 and 144/81 mm Hg, and glycosylated hemoglobin was 7.0% and 6.9% at baseline in the valsartan group and the amlodipine group, respectively. Both of them were equally controlled between the 2 groups during the study. The median follow-up period was 3.2 years, and primary outcome had occurred in 54 patients in the valsartan group and 56 in the amlodipine group (hazard ratio0.97 [95% CI0.66–1.40]; P=0.85). Patients in the valsartan group had a significantly lower incidence of heart failure than in the amlodipine group (hazard ratio0.20 [95% CI0.06–0.69]; P=0.01). Other components and all-cause mortality were not significantly different between the 2 groups. Composite cardiovascular outcomes were comparable between the valsartan- and amlodipine-based treatments in Japanese hypertensive patients with glucose intolerance. Admission because of heart failure was significantly less in the valsartan group.
subject
0Amlodipine - therapeutic use
1Antihypertensive agents
2Antihypertensive Agents - therapeutic use
3Arterial hypertension. Arterial hypotension
4Biological and medical sciences
5Blood and lymphatic vessels
6Blood Glucose - metabolism
7Blood Pressure - drug effects
8Cardiology. Vascular system
9Cardiovascular system
10Diabetes Mellitus, Type 2 - blood
11Diabetes Mellitus, Type 2 - complications
12Diabetes Mellitus, Type 2 - epidemiology
13Female
14Follow-Up Studies
15Glucose Intolerance
16Glycated Hemoglobin A - metabolism
17Humans
18Hypertension - complications
19Hypertension - drug therapy
20Hypertension - epidemiology
21Japan - epidemiology
22Male
23Medical sciences
24Middle Aged
25Morbidity - trends
26Pharmacology. Drug treatments
27Prospective Studies
28Risk Factors
29Survival Rate - trends
30Tetrazoles - therapeutic use
31Valine - analogs & derivatives
32Valine - therapeutic use
33Valsartan
issn
00194-911X
11524-4563
fulltextfalse
rsrctypearticle
creationdate2012
recordtypearticle
recordideNqNUV1v0zAUjRCIlcFfQBYS4inDdpyvPZFVpa002qmrgD1FTny7Ghy72M6q_h1-KQ4tIO0JS9bVuTr3-PieKHpD8AUhGXk_u7uZrNaTxe18uahmVWiSC1IwSrMn0YiklMUszZKn0QiTksUlIV_PohfOfcOYMMby59EZpTShJGGj6OfYdDtupTMaXYHfA2j0mSvHrecacS1Q1Skj5E5qQCu451ZIfY_GQzUP3LW94hZ9MraRQvrD74mAPFcDkhrNDjuwHrSTD4BuuJegvUNfpN-iqepb4wDNtTcKLNctXKJFNV3eVWg2qVZrdOt7cXgZPdsER_DqVM-j9cfJejyLr5fT-bi6jsOvcBZnBUtoxllCmqbMIN8wwEKwTVkWSZGxosQpLRhPgaU5azjBadnkrSibVrQiLfF59O4ou7PmRw_O1510LSjFNZje1eUgQfO8CMzLI7O1xjkLm3pnZcftoSa4HhKqHyUUmqQ-JhSGX5-e6ZsOxN_RP5EEwtsTIWyXq82wF-n-8dKUJpgNLj48ctFKH_ZrtLdcqv_zwo4Se6M8WPdd9Xuw9Ra48tsah8NoVsQUE4qTgOJwSYZ_AWDJwWw
startdate201203
enddate201203
creator
0Muramatsu, Takashi
1Matsushita, Kunihiro
2Yamashita, Kentaro
3Kondo, Takahisa
4Maeda, Kengo
5Shintani, Satoshi
6Ichimiya, Satoshi
7Ohno, Miyoshi
8Sone, Takahito
9Ikeda, Nobuo
10Watarai, Masato
11Murohara, Toyoaki
general
0American Heart Association, Inc
1Lippincott Williams & Wilkins
scope
0IQODW
1CGR
2CUY
3CVF
4ECM
5EIF
6NPM
7AAYXX
8CITATION
97X8
sort
creationdate201203
titleComparison Between Valsartan and Amlodipine Regarding Cardiovascular Morbidity and Mortality in Hypertensive Patients With Glucose Intolerance: NAGOYA HEART Study
authorMuramatsu, Takashi ; Matsushita, Kunihiro ; Yamashita, Kentaro ; Kondo, Takahisa ; Maeda, Kengo ; Shintani, Satoshi ; Ichimiya, Satoshi ; Ohno, Miyoshi ; Sone, Takahito ; Ikeda, Nobuo ; Watarai, Masato ; Murohara, Toyoaki
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-14406-684326a431bb96e7f4e0dd4f99838648905284a5e4574ba1059b7cd9bcdcd590
rsrctypearticles
prefilterarticles
languageeng
creationdate2012
topic
0Amlodipine - therapeutic use
1Antihypertensive agents
2Antihypertensive Agents - therapeutic use
3Arterial hypertension. Arterial hypotension
4Biological and medical sciences
5Blood and lymphatic vessels
6Blood Glucose - metabolism
7Blood Pressure - drug effects
8Cardiology. Vascular system
9Cardiovascular system
10Diabetes Mellitus, Type 2 - blood
11Diabetes Mellitus, Type 2 - complications
12Diabetes Mellitus, Type 2 - epidemiology
13Female
14Follow-Up Studies
15Glucose Intolerance
16Glycated Hemoglobin A - metabolism
17Humans
18Hypertension - complications
19Hypertension - drug therapy
20Hypertension - epidemiology
21Japan - epidemiology
22Male
23Medical sciences
24Middle Aged
25Morbidity - trends
26Pharmacology. Drug treatments
27Prospective Studies
28Risk Factors
29Survival Rate - trends
30Tetrazoles - therapeutic use
31Valine - analogs & derivatives
32Valine - therapeutic use
33Valsartan
toplevelpeer_reviewed
creatorcontrib
0Muramatsu, Takashi
1Matsushita, Kunihiro
2Yamashita, Kentaro
3Kondo, Takahisa
4Maeda, Kengo
5Shintani, Satoshi
6Ichimiya, Satoshi
7Ohno, Miyoshi
8Sone, Takahito
9Ikeda, Nobuo
10Watarai, Masato
11Murohara, Toyoaki
12NAGOYA HEART Study Investigators
13for the NAGOYA HEART Study Investigators
collection
0Pascal-Francis
1Medline
2MEDLINE
3MEDLINE (Ovid)
4MEDLINE
5MEDLINE
6PubMed
7CrossRef
8MEDLINE - Academic
jtitleHypertension (Dallas, Tex. 1979)
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
au
0Muramatsu, Takashi
1Matsushita, Kunihiro
2Yamashita, Kentaro
3Kondo, Takahisa
4Maeda, Kengo
5Shintani, Satoshi
6Ichimiya, Satoshi
7Ohno, Miyoshi
8Sone, Takahito
9Ikeda, Nobuo
10Watarai, Masato
11Murohara, Toyoaki
aucorp
0NAGOYA HEART Study Investigators
1for the NAGOYA HEART Study Investigators
formatjournal
genrearticle
ristypeJOUR
atitleComparison Between Valsartan and Amlodipine Regarding Cardiovascular Morbidity and Mortality in Hypertensive Patients With Glucose Intolerance: NAGOYA HEART Study
jtitleHypertension (Dallas, Tex. 1979)
addtitleHypertension
date2012-03
risdate2012
volume59
issue3
spage580
epage586
pages580-586
issn0194-911X
eissn1524-4563
codenHPRTDN
abstractIt has not been fully examined whether angiotensin II receptor blocker is superior to calcium channel blocker to reduce cardiovascular events in hypertensive patients with glucose intolerance. A prospective, open-labeled, randomized, controlled trial was conducted for Japanese hypertensive patients with type 2 diabetes mellitus or impaired glucose tolerance. A total of 1150 patients (women34%; mean age63 years; diabetes mellitus82%) were randomly assigned to receive either valsartan- or amlodipine-based antihypertensive treatment. Primary outcome was a composite of acute myocardial infarction, stroke, coronary revascularization, admission attributed to heart failure, or sudden cardiac death. Blood pressure was 145/82 and 144/81 mm Hg, and glycosylated hemoglobin was 7.0% and 6.9% at baseline in the valsartan group and the amlodipine group, respectively. Both of them were equally controlled between the 2 groups during the study. The median follow-up period was 3.2 years, and primary outcome had occurred in 54 patients in the valsartan group and 56 in the amlodipine group (hazard ratio0.97 [95% CI0.66–1.40]; P=0.85). Patients in the valsartan group had a significantly lower incidence of heart failure than in the amlodipine group (hazard ratio0.20 [95% CI0.06–0.69]; P=0.01). Other components and all-cause mortality were not significantly different between the 2 groups. Composite cardiovascular outcomes were comparable between the valsartan- and amlodipine-based treatments in Japanese hypertensive patients with glucose intolerance. Admission because of heart failure was significantly less in the valsartan group.
copHagerstown, MD
pubAmerican Heart Association, Inc
pmid22232134
doi10.1161/HYPERTENSIONAHA.111.184226
oafree_for_read